Idogen AB announced that Christina Brattström has been appointed Chief Medical Officer. She has solid experience in clinical development of transplantation drugs, and over 20 years of experience in senior medical roles at international pharmaceutical companies. Christina Brattström will be part of the company's executive management and will take up her post on 1 April 2020. Since 2000, she has held several senior positions in the pharmaceutical industry and will bring a broad range of experience from both the clinical development and regulatory spheres. Previously, Christina Brattström worked at Wyeth in roles including Senior Medical Advisor and head of CRA Group with responsibility for clinical trials. In addition, Christina worked for Abbot as Medical Director and head of one of the company's regulatory affairs groups. She comes most recently from the pharmaceutical company Bayer AB, where she was Medical Director Scandinavia with medical responsibilities that included haemophilia drugs. Christina Brattström will take up a role in the development group that is preparing Idogen's tolerogenic cell therapy for clinical trials. The first trial of the company's most advanced project, IDO-8, is expected to begin in early 2021.